by Madaline Spencer | Jun 16, 2026
The US Food and Drug Administration (FDA) has approved an expanded indication for Hympavzi (marstacimab) to include treatment of patients with hemophilia A or B who are 12 years and older with inhibitors, as well as pediatric patients (ages 6 to 11 years) with or...
by Madaline Spencer | Jun 16, 2026
Carolina Barnett-Tapia, MD, Neuromuscular Neurologist and the University of Toronto, discusses the safety and efficacy of subcutaneous efgartigimod PH20 in ocular myasthenia gravis (oMG). oMG is a neuromuscular disease characterized by autoantibody...
by Madaline Spencer | Jun 15, 2026
Jeff Guptill, MD, Neuromuscular Clinical Development Lead at Argenx, discusses the impact of the Vyvgart (efgartigimod alfa) approval on the myasthenia gravis (MG) community to treat patients with anti-MuSK-Ab positive, anti-LRP4-Ab positive, and/or triple...
by Madaline Spencer | Jun 12, 2026
Kerrie-Anne Ho, PhD, Patient Preference Lead at UCB, discusses preferences and perceptions of acute seizure medications. Data from interviews with people with seizures (PwS) and caregiver interviews were presented at the American Academy of Neurology...
by Madaline Spencer | Jun 10, 2026
Abigail Schwaede, MD, Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses results on intravenous efgartigimod in juvenile generalized myasthenia gravis (gMG). gMG is a chronic autoimmune neuromuscular...
